Scott L. Burrows - 01 Sep 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Chief Financial Officer
Issuer ticker: SYRE
Reported as of: 01 Sep 2026
Net transaction value: -$2,283,821
SEC form: 4
Accepted by SEC: 03 Sep 2026, 21:33:44 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones, as Attorney-in-Fact

Key filing fact

Scott L. Burrows filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 03 Sep 2026.

Key facts

This page summarizes Scott L. Burrows's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
7 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Sep 2026, 21:33.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: -$2,283,821.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001853327 Primary reporting owner

Burrows Scott L

Relationship: Chief Financial Officer
Address: 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM
Signature: /s/ Heidy King-Jones, as Attorney-in-Fact
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRE transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,500
Change %: +7.7%
Price: $14.50^*
Shares after: 105,494
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1

SYRE transaction

Common Stock

Sale

Transaction value: $77,625
Shares: -900
Change %: -0.85%
Price: $86.25
Shares after: 104,594
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2

SYRE transaction

Common Stock

Sale

Transaction value: $381,890
Shares: -4,384
Change %: -4.2%
Price: $87.11
Shares after: 100,210
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F3

SYRE transaction

Common Stock

Sale

Transaction value: $177,468
Shares: -2,016
Change %: -2%
Price: $88.03
Shares after: 98,194
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F4

SYRE transaction

Common Stock

Sale

Transaction value: $17,808
Shares: -200
Change %: -0.2%
Price: $89.04
Shares after: 97,994
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F5

SYRE transaction

Common Stock

Sale

Transaction value: $1,629,029
Shares: -18,232
Change %: -19%
Price: $89.35
Shares after: 79,762
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F6, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -7,500
Change %: -2.2%
Price: $0.000000^*
Shares after: 337,357
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price: $14.50
Footnotes: F1, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 8 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

Footnote F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 to $86.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.60 to $87.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.64 to $88.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F6

The transaction reported reflects the sale of shares of the Issuer's common stock in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person.

Footnote F7

Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer.

Footnote F8

This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.